Catalpa carries 100M people in its mission, 15–20 portcos in its plan, €30M in its vehicle, Q1 2027 in its calendar, and a 3× minimum at fund level. The composition of those numbers — per portco, per diligence call, per LP review — is the operational question this case takes up.
two portcos signed · 13–18 to go · 10 months to final close
Three pressures at the fund level. One triangle at every portco. The 100M-people claim runs between them.
- Demographic Inversion · the aging curve · the dependency ratio
- Shortage of Healthcare Professionals · supply collapse against demand
- Escalating Costs · the unit-economics ceiling
"To succeed in healthtech you must serve all three — patient, practitioner, payer."
FIG. ── PATIENT · PRACTITIONER · PAYER · SERVE ALL THREE OR FAIL ONE
Per portco: a trajectory toward 5–7M people served, defensible separately on patient outcomes, practitioner adoption, and payer reimbursement.
Noah Labs (cardiac vocal biomarker · 30% admission reduction · reimbursed) and Remi Health (DaaS · 1M+ tests · cross-border) compose the triangle differently. The 100M claim has to compose across them all.
Thirteen to eighteen portcos sit between today and final close. Each enters the triangle from a different position. Does the regime sit in partner memory, or in something inspectable?
Each row carries its own definition of "evidence." The triangle composes per row; the 100M aggregate composes across rows.
FIG. ── PER-PORTCO EVIDENCE REGIME · 4 ARCHETYPES × PATIENT · PRACTITIONER · PAYER · REGULATORY
Noah Labs anchors the reimbursed-clinical row · Remi Health anchors the infrastructure row · two slots open
Queryable Fund reads two primitives into the Catalpa stack — audit chain and methodology overlay. Diligence stops being memory work.
Every evidence event — regulatory filing, reimbursement code, prescribing-physician count, country compliance step, outcome cohort — appends to a hash-chained log, mode-tagged. Append-only. Never-deletable. The 100M composition is reconstructible at any IC call, LP update, or SFDR refresh without interrupting partners.
Per-portco regime spec as inspectable YAML — patient row, practitioner row, payer row, regulatory class, country footprint. Sperling and Christian Goergen's diligence judgments encoded once; the next portco inherits the structure. Versioned. Survives partner turnover and the SFDR 2.0 transition.
FIG. ── AUDIT CHAIN · MODE-TAGGED · HASH-LINKED · APPEND-ONLY · NEVER-DELETABLE
the LP-defensibility layer of the fund's own published math
Q1 2027 is ten months out. The 100M claim has to hold against every diligence call, every LP review, and every regulatory remap across that window.
Five months past first close. Two portcos signed. Thirteen to eighteen to go. The second tranche of €20M still has to be raised.
The SFDR 2.0 categories — Transition · ESG Basics · Sustainable — were published November 2025 and land for entry in 2028, inside Catalpa's first deployment cycle. The audit chain's mode tags carry the remap natively; disclosure regenerates from the chain rather than being rebuilt against it.
ONE ARCHETYPE ROW · ONE METHODOLOGY OVERLAY · AUDIT-CHAIN STUB · REAL CATALPA DILIGENCE MATERIAL
Pressure-test the substrate. Ask where it breaks.
The substrate answers in its own voice — the same primitive we'd install on one of your archetype rows. Not a demo. The actual reasoning surface.
STREAMING · κ ≥ 0.85 · ANONYMITY HOLDS · CITATIONS BY DEFAULT
A Phase 0 PoC scoped to one archetype row from §02 — run on real Catalpa diligence material.
Delivered as an audit-chain stub plus one methodology-overlay YAML the partners can mark up. This case is operator-anonymous. Open-ended timing; the page stays live.
If relevant, I can send a short async questionnaire — no call needed — and build a no-charge synthetic-data Phase 0 PoC "Catalpa AI OS". Within two weeks, replay one portco's triangle evidence chain against the 100M-people composition test before LPs start citing it in Q1 2027 final-close diligence.
Youth flourishing · outcomes-tied diligence · methodology overlay encoded at fund formation.
Healthtech specialist · pre-clinical evidence asymmetry · dual-pathway diligence as substrate.
Youth mental health · evidence-mode tagging across pre-clinical signal and lived experience.